The Value of PET Imaging Targeting Granzyme B in Predicting Efficacy and Prognosis in T-NK Cell Lymphoma
NCT06863441 · Status: NOT_YET_RECRUITING · Type: OBSERVATIONAL · Enrollment: 50
Last updated 2025-03-07
Summary
The study on the value of PET imaging targeting granzyme B in predicting the efficacy and prognosis of T-NK cell lymphoma.
Conditions
- T-NK Cell Lymphoma
Sponsors & Collaborators
-
Ruijin Hospital
lead OTHER
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2025-03-01
- Primary Completion
- 2029-12-31
- Completion
- 2029-12-31
Countries
- China
Study Locations
More Related Trials
-
Granzyme B-targeted PET Imaging Monitoring Tumor Responses to Immunotherapy
NCT06916442 ·Status: NOT_YET_RECRUITING
-
The Value of 68Ga-grazytracer PET in Monitoring Responses to Immunotherapy of Gastrointestinal Malignancies
NCT06644274 ·Status: RECRUITING
-
The Application of 18F-G1 PET/CT Targeting Granzyme B in the Pan-cancer Immunotherapy
NCT07039474 ·Status: NOT_YET_RECRUITING
-
18F-FDG PET/CT-based Prognostic Model for Predicting Outcome in Patients With Diffuse Large B-cell Lymphoma
NCT02928861 ·Status: UNKNOWN ·Phase: NA
-
Diagnostic Comparison of PET-magnetic Resonance and PET-CT in Patients With Oncologic Diseases
NCT02316431 ·Status: COMPLETED
-
CD70-targeted immunoPET Imaging of Malignant Cancers
NCT06852638 ·Status: RECRUITING ·Phase: PHASE2
-
The Value of 68Ga-grazytracer PET in Monitoring Responses to Immunotherapy of Advanced Hepatobiliary Malignancy
NCT06597539 ·Status: RECRUITING
-
Evaluating 18F-FDG PET/CT With Liver SUVmax-based Criteria for Prognosis of Patients With Diffuse Large B-cell Lymphoma
NCT02931201 ·Status: UNKNOWN ·Phase: NA
-
18F-FDG PET Radiomics of Diffuse Large B-cell Lymphoma
NCT04317313 ·Status: COMPLETED
-
PET/CT-Based Image Analysis and Machine Learning of Hypermetabolic Pulmonary Lesions
NCT06602674 ·Status: COMPLETED
-
Granzyme B PET Imaging Drug as a Predictor of Immunotherapy Response to Checkpoint Inhibitors
NCT04169321 ·Status: COMPLETED ·Phase: PHASE1
-
The Prognostic Value of Interim PET/CT After 2 Cycles of Chemotherapy in Predicting Progression of Non Hodgkins Lymphoma
NCT00498667 ·Status: WITHDRAWN
-
PET With Respiratory Gating Technique in Evaluation of Response and Normal Tissue Effect in Thoracic Cancer
NCT02063633 ·Status: UNKNOWN
-
A Prospective, Multicenter, Diagnostic Study Evaluating 68Ga-BCMA PET/CT for Targeting BCMA Expression in Multiple Myeloma.
NCT07319897 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2/PHASE3
-
68Ga-DOTA-hLAG-3 PET Imaging of LAG-3 Expression in Cancers
NCT05346276 ·Status: COMPLETED
-
The Performance of Multi-tracer Multimodality PET in Lymphoma
NCT05004961 ·Status: UNKNOWN
-
Comparison of Whole-body MRI, Circulating DNA and PET-CT in Staging, Prognosis, and Treatment Response in Patients with Diffuse Large Cell B Lymphoma
NCT06777290 ·Status: COMPLETED
-
68Ga-grazytracer PET/CT of Tumor Responses to Immunotherapy
NCT05000372 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
The Value of 68Ga-grazytracer PET in Monitoring Responses to Immunotherapy of Pancreatic Cancer.
NCT06601010 ·Status: RECRUITING
-
18F-mFBG PET Imaging in the Evaluation of Neuroblastoma
NCT06852807 ·Status: RECRUITING
-
Application of 68Ga NEB PET Imaging in the Diagnosis and Evaluation of Lymphatic Disorders
NCT04273334 ·Status: UNKNOWN ·Phase: PHASE1
-
PET MRI as a Staging Tool for Head and Neck Cancer
NCT04750434 ·Status: COMPLETED
-
Head-to-head Comparison Between [18F]-FDG PET/CT and PET/MRI in Lymphomas
NCT05390632 ·Status: UNKNOWN
-
68Ga-DOTA-F2 PET/CT in Patients With Various Types of Cancer
NCT05637034 ·Status: UNKNOWN ·Phase: NA
-
68Ga-NYM096 PET/CT in Various Kinds of Cancer
NCT07144748 ·Status: RECRUITING ·Phase: NA